# A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

> **NCT00985374** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 11 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** RAD001
- **DRUG:** RG1507

## Key facts

- **NCT ID:** NCT00985374
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985374, "A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00985374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*